Literature DB >> 22532696

Antibodies against the gH/gL/UL128/UL130/UL131 complex comprise the majority of the anti-cytomegalovirus (anti-CMV) neutralizing antibody response in CMV hyperimmune globulin.

Ashley E Fouts1, Pamela Chan, Jean-Philippe Stephan, Richard Vandlen, Becket Feierbach.   

Abstract

Anti-cytomegalovirus (anti-CMV) hyperimmune globulin (HIG) has demonstrated efficacy in preventing CMV disease in solid-organ transplant patients as well as congenital disease when administered to pregnant women. To identify the neutralizing component of cytomegalovirus hyperimmune globulin (CMV-HIG), we performed serial depletions of CMV-HIG on cell-surface-expressed CMV antigens as well as purified antigens. Using this approach, we demonstrate that the major neutralizing antibody response is directed at the gH/gL/UL128/UL130/UL131 complex, suggesting little role for anti-gB antibodies in CMV-HIG neutralization.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22532696      PMCID： PMC3416310          DOI： 10.1128/JVI.00467-12

Source DB:  PubMed          Journal:  J Virol        ISSN： 0022-538X            Impact factor:   5.103


  21 in total

1.  gp120: Biologic aspects of structural features.

Authors:  P Poignard; E O Saphire; P W Parren; D R Burton
Journal:  Annu Rev Immunol       Date:  2001       Impact factor: 28.527

2.  A further analysis of primary cytomegalovirus disease prevention in renal transplant recipients with a cytomegalovirus immune globulin: interim comparison of a randomized and an open-label trial.

Authors:  D R Snydman; B G Werner; N L Tilney; R L Kirkman; E L Milford; S I Cho; H L Bush; A S Levey; T B Strom; C B Carpenter
Journal:  Transplant Proc       Date:  1988-12       Impact factor: 1.066

3.  Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal-transplant recipients.

Authors:  D R Snydman; B G Werner; B Heinze-Lacey; V P Berardi; N L Tilney; R L Kirkman; E L Milford; S I Cho; H L Bush; A S Levey
Journal:  N Engl J Med       Date:  1987-10-22       Impact factor: 91.245

4.  Quantitative analysis of neutralizing antibody response to human cytomegalovirus in natural infection.

Authors:  Dai Wang; Fengsheng Li; Daniel C Freed; Adam C Finnefrock; Aimin Tang; Shannon N Grimes; Danilo R Casimiro; Tong-Ming Fu
Journal:  Vaccine       Date:  2011-09-22       Impact factor: 3.641

5.  Cell surface expression of human cytomegalovirus (HCMV) gp55-116 (gB): use of HCMV-recombinant vaccinia virus-infected cells in analysis of the human neutralizing antibody response.

Authors:  W J Britt; L Vugler; E J Butfiloski; E B Stephens
Journal:  J Virol       Date:  1990-03       Impact factor: 5.103

6.  Maternal immunity and prevention of congenital cytomegalovirus infection.

Authors:  Karen B Fowler; Sergio Stagno; Robert F Pass
Journal:  JAMA       Date:  2003-02-26       Impact factor: 56.272

7.  Human cytomegalovirus UL131-128 genes are indispensable for virus growth in endothelial cells and virus transfer to leukocytes.

Authors:  Gabriele Hahn; Maria Grazia Revello; Marco Patrone; Elena Percivalle; Giulia Campanini; Antonella Sarasini; Markus Wagner; Andrea Gallina; Gabriele Milanesi; Ulrich Koszinowski; Fausto Baldanti; Giuseppe Gerna
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

8.  Antibodies to recombinant-derived glycoprotein B after natural human cytomegalovirus infection correlate with neutralizing activity.

Authors:  G S Marshall; G P Rabalais; G G Stout; S L Waldeyer
Journal:  J Infect Dis       Date:  1992-02       Impact factor: 5.226

9.  Correction of multi-gene deficiency in vivo using a single 'self-cleaving' 2A peptide-based retroviral vector.

Authors:  Andrea L Szymczak; Creg J Workman; Yao Wang; Kate M Vignali; Smaroula Dilioglou; Elio F Vanin; Dario A A Vignali
Journal:  Nat Biotechnol       Date:  2004-04-04       Impact factor: 54.908

10.  Virus-specific IgG and IgM antibodies in normal and immunocompromised subjects infected with cytomegalovirus.

Authors:  L Rasmussen; D Kelsall; R Nelson; W Carney; M Hirsch; D Winston; J Preiksaitis; T C Merigan
Journal:  J Infect Dis       Date:  1982-02       Impact factor: 5.226
View more
  101 in total

1.  A trimeric capable gB CMV vaccine provides limited protection against a highly cell associated and epithelial tropic strain of cytomegalovirus in guinea pigs.

Authors:  K Yeon Choi; Nadia S El-Hamdi; Alistair McGregor
Journal:  J Gen Virol       Date:  2021-03-17       Impact factor: 3.891

2.  Cytomegalovirus Virions Shed in Urine Have a Reversible Block to Epithelial Cell Entry and Are Highly Resistant to Antibody Neutralization.

Authors:  Xiaohong Cui; Stuart P Adler; Mark R Schleiss; Ravit Arav-Boger; Gail J Demmler Harrison; Michael A McVoy
Journal:  Clin Vaccine Immunol       Date:  2017-06-05

Review 3.  Cytomegalovirus vaccines.

Authors:  Michael A McVoy
Journal:  Clin Infect Dis       Date:  2013-12       Impact factor: 9.079

4.  In Vitro Characterization of Human Cytomegalovirus-Targeting Therapeutic Monoclonal Antibodies LJP538 and LJP539.

Authors:  Hetalkumar D Patel; Pavel Nikitin; Thomas Gesner; James J Lin; David T Barkan; Claudio Ciferri; Andrea Carfi; Tahmineh Akbarnejad Yazdi; Peter Skewes-Cox; Brigitte Wiedmann; Nadine Jarousse; Weidong Zhong; Adam Feire; Christy M Hebner
Journal:  Antimicrob Agents Chemother       Date:  2016-07-22       Impact factor: 5.191

5.  Phase 1 Randomized, Double-Blind, Placebo-Controlled Study of RG7667, an Anticytomegalovirus Combination Monoclonal Antibody Therapy, in Healthy Adults.

Authors:  Julie H Ishida; Tracy Burgess; Michael A Derby; Pearline A Brown; Mauricio Maia; Rong Deng; Brinda Emu; Becket Feierbach; Ashley E Fouts; X Charlene Liao; Jorge A Tavel
Journal:  Antimicrob Agents Chemother       Date:  2015-06-08       Impact factor: 5.191

6.  Impact of Antibodies and Strain Polymorphisms on Cytomegalovirus Entry and Spread in Fibroblasts and Epithelial Cells.

Authors:  Xiaohong Cui; Daniel C Freed; Dai Wang; Ping Qiu; Fengsheng Li; Tong-Ming Fu; Lawrence M Kauvar; Michael A McVoy
Journal:  J Virol       Date:  2017-06-09       Impact factor: 5.103

7.  Recombinant cytomegalovirus glycoprotein B vaccine: Rethinking the immunological basis of protection.

Authors:  Mark R Schleiss
Journal:  Proc Natl Acad Sci U S A       Date:  2018-06-06       Impact factor: 11.205

8.  Developing a Vaccine against Congenital Cytomegalovirus (CMV) Infection: What Have We Learned from Animal Models? Where Should We Go Next?

Authors:  Mark R Schleiss
Journal:  Future Virol       Date:  2013-12       Impact factor: 1.831

9.  Coding potential of UL/b' from the initial source of rhesus cytomegalovirus Strain 68-1.

Authors:  Rachel B Gill; J Jason Bowman; Tammy Krogmann; Kurt Wollenberg; David M Asher; Jeffrey I Cohen
Journal:  Virology       Date:  2013-10-02       Impact factor: 3.616

10.  Pentameric complex of viral glycoprotein H is the primary target for potent neutralization by a human cytomegalovirus vaccine.

Authors:  Daniel C Freed; Qi Tang; Aimin Tang; Fengsheng Li; Xi He; Zhao Huang; Weixu Meng; Lin Xia; Adam C Finnefrock; Eberhard Durr; Amy S Espeseth; Danilo R Casimiro; Ningyan Zhang; John W Shiver; Dai Wang; Zhiqiang An; Tong-Ming Fu
Journal:  Proc Natl Acad Sci U S A       Date:  2013-12-02       Impact factor: 11.205
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.